2011 young Surgeon's award winner: High endothelial venules: A novel prognostic marker in cancer metastasis and the missing link?

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 1, 2012, Pages 21-28

  Lee, Ser Yee ^a,b   Qian, Chao Nan ^c,d   Ooi, Aik Seng ^c   Chen, Peiyi ^e   Tan, Veronique K M ^a   Chia, Claramae S ^a   Hwang, Jacqueline S G ^a   Teh, Bin Tean ^b,c   Soo, Khee Chee ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angioegenesis; Cancer metastasis; High endothelial venules

Indexed keywords

ARTICLE; CANCER MORPHOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; HIGH ENDOTHELIAL VENULE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METAMORPHOSIS; MOLECULAR DYNAMICS; OVERALL SURVIVAL; PHENOTYPE; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR VASCULARIZATION; VENULE;

EID: 84863034804     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Silverman S. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001;132 Suppl:7S-11S.
3. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries L, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
4. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.
5. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, et al. Preparing the soil: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006;66:10365-76.
6. Qian CN, Resau JH, Teh BT. Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle 2007;6:514-7.
7. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
8. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987;10:5-9.
9. Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994;25:498-505.
10. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007;26:645-62.
11. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91.
12. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen M, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001;7:199-205.
13. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
14. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82.
15. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 2005;22:31-8.
16. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66:2650-7.
17. Zwaans BM, Bielenberg DR. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 2007;74:145-58.
18. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib effcacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45.
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
20. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
21. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006;177:3369-79.
22. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003;163:69-79.
23. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
24. Rosen PP, Saigo PE, Braun DW, Weathers E, DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg 1981;193:15-25.
25. Leong SP. Paradigm shift of staging and treatment for early breast cancer in the sentinel lymph node era. Breast J 2006;12:S128-33.
26. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005;23:8461-8.
27. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
28. Qian CN, Zhang CQ, Guo X, Hong MH, Cao SM, Mai WY, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000;88:255-61.
29. Macfarlane GJ, Boyle P, Scully C. Rising mortality from cancer of the tongue in young Scottish males. Lancet 1987;2:912.
30. Shemen LJ, Klotz J, Schottenfeld D, Strong EW. Increase of tongue cancer in young men. JAMA 1984;252:1857.
31. Pitman KT. Sentinel node localization in head and neck tumors. Semin Nucl Med 2005;35:253-6.
32. Yeh JC, Hiraoka N, Petryniak B, Nakayama J, Ellies LG, Rabuka D, et al. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell 2001;105:957-69.
33. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al. Endothelial cell diversity revealed by global expression profling. Proc Natl Acad Sci USA 2003;100:10623-8.
34. Lacorre DA, Baekkevold ES, Garrido I, Brandtzaeg P, Haraldsen G, Amalric F, et al. Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment. Blood 2004;103:4164-72.
35. Nieder C, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol 2002;3:33-40.